Vaxcyte, Inc. Stock price

Equities

PCVX

US92243G1085

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 03:53:48 2024-03-28 pm EDT 5-day change 1st Jan Change
68.37 USD -0.19% Intraday chart for Vaxcyte, Inc. +1.57% +9.40%
Sales 2024 * - Sales 2025 * - Capitalization 7.43B
Net income 2024 * -464M Net income 2025 * -509M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-16.1 x
P/E ratio 2025 *
-15.2 x
Employees 254
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85.77%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.60%
1 week-0.91%
Current month-7.21%
1 month-15.48%
3 months+8.03%
6 months+33.24%
Current year+9.08%
More quotes
1 week
66.06
Extreme 66.06
69.07
1 month
66.06
Extreme 66.06
76.39
Current year
53.83
Extreme 53.83
82.04
1 year
34.11
Extreme 34.11
82.04
3 years
15.51
Extreme 15.51
82.04
5 years
15.51
Extreme 15.51
82.04
10 years
15.51
Extreme 15.51
82.04
More quotes
Managers TitleAgeSince
Founder 60 13-05-26
Founder 56 13-05-26
Director of Finance/CFO 55 20-04-30
Members of the board TitleAgeSince
Founder 56 13-05-26
Director/Board Member 58 21-09-15
Director/Board Member 73 21-10-26
More insiders
Date Price Change Volume
24-03-28 68.65 +0.22% 244 659
24-03-27 68.5 +1.60% 523,354
24-03-26 67.42 +1.58% 548,809
24-03-25 66.37 -1.28% 379,932
24-03-22 67.23 -0.61% 366,085

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Vaxcyte Inc. is a clinical-stage vaccine company. The Company develops conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its synthetic techniques include advanced chemistry and the XpressCF cell-free protein synthesis platform, licensed from Sutro Biopharma, Inc., or Sutro Biopharma. Its pipeline includes Pneumococcal conjugate vaccine (PCV), VAX-A1, VAX-PG and VAX-GI. Its lead vaccine candidate, VAX-24, is a 24-valent investigational PCV being developed for the prevention of invasive pneumococcal disease (IPD). Its second PCV candidate, VAX-31, is designed to prevent IPD. population. VAX- 24 is intended to improve upon the standard-of-care PCV vaccines for both children and adults. VAX-A1 is a conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus or Group A Strep. VAX-PG is a protein vaccine candidate targeting the keystone pathogen responsible for periodontitis. VAX-GI is a vaccine program designed to prevent Shigella.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
68.5 USD
Average target price
103.3 USD
Spread / Average Target
+50.78%
Consensus
  1. Stock
  2. Equities
  3. Stock Vaxcyte, Inc. - Nasdaq